121Consequently, in order to establish the existence of appreciable potential or real effects on competition of settlement agreements such as those at issue in the main proceedings, the referring court does not have to find either that the manufacturer of generic medicines who is a party to that agreement would probably have been successful in the patent proceedings, or that the parties to that agreement would probably have concluded a less restrictive settlement agreement.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.